High-Resolution Ex Vivo Tissue Clearing, Lightsheet Imaging, and Data Analysis to Support Macromolecular Drug and Biomarker Distribution in Whole Organs and Tumors.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Works matching AU Freshwater, Tomoko
Results: 13
1
2
A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 7, p. 770, doi. 10.1002/cpdd.1400
- By:
- Publication type:
- Article
3
Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 5, p. 1304, doi. 10.1002/cpt.3379
- By:
- Publication type:
- Article
4
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically‐Based Modeling.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 623, doi. 10.1002/cpt.2937
- By:
- Publication type:
- Article
5
Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 1, p. 200, doi. 10.1002/cpt.2170
- By:
- Publication type:
- Article
6
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 2, p. 189, doi. 10.1007/s00280-021-04274-6
- By:
- Publication type:
- Article
7
Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.705443
- By:
- Publication type:
- Article
8
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
9
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 3, p. 241, doi. 10.1007/s10637-024-01428-0
- By:
- Publication type:
- Article
10
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 1, p. 145, doi. 10.1007/s10637-023-01410-2
- By:
- Publication type:
- Article
11
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3
- By:
- Publication type:
- Article
12
A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1211452
- By:
- Publication type:
- Article
13
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 11, p. 1493, doi. 10.1002/jcph.1935
- By:
- Publication type:
- Article